EI
BBIO icon

EFG International’s BridgeBio Pharma BBIO Stock Holding History

EFG International’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.12M Sell
82,172
-1,557
-2% -$109K 0.11% 152
2026
Q1 		$6.22M Sell
83,729
-4,526
-5% -$328K 0.13% 137
2025
Q4 		$6.75M Buy
+88,255
New +$5.79M 0.13% 135

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

EFG International's BBIO Position: Q2 2026 in Review

EFG International reduced its BridgeBio Pharma (BBIO) stake by 1.9% in Q2 2026, selling an estimated $109K and leaving 82,172 shares worth $6.12M. The position accounts for 0.11% of the portfolio, ranked #152.

EFG International first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.75M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • EFG International held 82,172 shares of BridgeBio Pharma worth $6.12M as of Q2 2026.
  • EFG International sold 1,557 BridgeBio Pharma shares in Q2 2026, an estimated $109K.
  • BridgeBio Pharma made up 0.11% of EFG International's portfolio in Q2 2026, its #152 holding.
  • EFG International first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • EFG International's BridgeBio Pharma position peaked at $6.75M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.